|1.||Zamponi, Gerald W: 5 articles (10/2015 - 01/2004)|
|2.||Kiso, Tetsuo: 4 articles (08/2015 - 05/2010)|
|3.||Qin, Ning: 4 articles (05/2014 - 12/2006)|
|4.||Flores, Christopher M: 4 articles (05/2014 - 12/2006)|
|5.||Lubin, Mary Lou: 4 articles (05/2014 - 12/2006)|
|6.||Swensen, Andrew M: 4 articles (09/2013 - 01/2011)|
|7.||Ogiyama, Takashi: 3 articles (08/2015 - 12/2014)|
|8.||Gotoh, Takayasu: 3 articles (08/2015 - 12/2014)|
|9.||Watanabe, Toshihiro: 3 articles (08/2015 - 12/2014)|
|10.||Koakutsu, Akiko: 3 articles (08/2015 - 12/2014)|
06/15/2012 - "Selective blockers of the N-type calcium channel have proven to be effective in animal models of chronic pain. "
05/15/2001 - "In particular, the N-type VDCC has attracted attention, because inhibitors of this channel are effective in various aspects of pain-related phenomena. "
06/01/2000 - "Preliminary studies of the N-type calcium channel antagonists for the treatment of acute and chronic pain are promising but too early to enable researchers to make firm conclusions. "
10/01/2015 - "Use-dependent N-type calcium channel blockers are likely to be of therapeutic use in chronic pain conditions. "
04/01/2014 - "N-type calcium channels play important roles in the control of neurotransmission release and transmission of pain signals to the central nervous system. "
|2.||Hypertension (High Blood Pressure)
12/01/2012 - "L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension."
11/01/2012 - "The N-type calcium channel blockade that inhibits renal sympathetic nerve activity might reduce glomerular hypertension by facilitating vasodilation of the efferent arterioles. "
10/01/2007 - "L/N-type calcium channel blockers exhibit sympatholytic action and a renal protective effect via dilation of afferent and efferent arterioles of the renal glomerulus, and afford more potent protection against hypertension-related organ damage than L-type calcium channel blockers. "
10/01/2009 - "The current study was conducted to examine the effects of cilnidipine, a dual L/N-type calcium channel blocker, on blood pressure, pulse rate, and autonomic functions in patients with mild-to-moderate hypertension. "
02/01/2013 - "The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE."
|3.||Neuralgia (Stump Neuralgia)
08/01/2015 - "Discovery of an 8-methoxytetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain without CYP inhibition liability."
08/01/2015 - "N-type calcium channel blockade is a promising therapeutic approach for the treatment of neuropathic pain. "
08/01/2015 - "Discovery of a 1-isopropyltetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain."
12/15/2014 - "N-type calcium channels represent a promising target for the treatment of neuropathic pain. "
07/18/2014 - "Although the mechanism of its activation is not clear at present, activation of N-type VDCC expressed in non-excitable microglial cells contributes to the pathophysiology of neuropathic pain. "
08/01/2013 - "L-/N-type calcium channel blockers and proteinuria."
08/01/2013 - "Thus, L-/N-type calcium channel blockers are one of suitable candidates for the second-line antihypertensives in the renin-angiotensin system inhibitor-treated hypertensive patients with proteinuria. "
05/01/2010 - "Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte."
04/01/2011 - "L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats."
05/01/2010 - "Clinical studies have indicated the beneficial effect of an L/N-type calcium channel blocker (CCB), cilnidipine, on the progression of proteinuria in hypertensive patients compared with an L-type CCB, amlodipine. "
02/01/2011 - "Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus."
02/01/2011 - "Cilnidipine which inhibits N-type calcium channels is more useful for patients with hypertension and diabetes mellitus from its effects on glucose and lipid metabolism and renal function."
02/01/2011 - "This study was undertaken to compare the efficacy of amlodipine (an inhibitor of L-type calcium channels) and cilnidipine (an inhibitor of both L-type and N-type calcium channels) in patients with hypertension and type II diabetes mellitus. "
|4.||L-Type Calcium Channels (Dihydropyridine Receptor)
|6.||Calcium Channels (Calcium Channel)
|10.||Opioid Analgesics (Opioids)
|5.||Cardiopulmonary Resuscitation (CPR)